In another study published this year, Paik et al demonstrated potent activity of TAK‐228 in NSCLC models harboring Nrf2 activating alterations35 and confirmed single agent clinical activity in genomically selected squamous cell lung cancer with NFE2L2/KEAP1 alterations, while also suggesting a role for combination therapy in treatment resistant patients.35 This evidence concerns the gene KEAP1 and non-small cell lung carcinoma.